SAN FRANCISCO--(BUSINESS WIRE)--Forest Laboratories, Inc (NYSE: FRX) today presented at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco new data from a complete analysis of FOCUS 1 and FOCUS 2, two global multicenter Phase III studies of ceftaroline for the treatment of community-acquired pneumonia (CAP) in hospitalized patients. Detailed analyses from the previously reported top-line data of the two pivotal trials demonstrated that ceftaroline administered intravenously met the primary endpoint of non-inferiority in patients with moderate to severe CAP requiring hospitalization.1 Ceftaroline therapy was also generally well tolerated, with an adverse event profile similar to ceftriaxone.
